Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly Smith

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
The Lancet. Infectious Diseases|February 9, 2019
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trialMichael Aboud, Richard Kaplan, Johannes Lombaard, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 21, 2023
End Point Considerations for Clinical Trials in Enteric HyperoxaluriaCraig B Langman, Dean Assimos, Melanie Blank, et al.
Antimicrobial Agents and Chemotherapy|January 3, 2022
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the <i>In Vitro</i> Potency of Cabotegravir or RilpivirineJerry L Jeffrey, Marty St Clair, Ping Wang, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
The American Journal of Cardiology|February 2, 2008
Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary interventionProbal Roy, Ashesh N Buch, Aamir Javaid, et al.
The American Journal of Cardiology|March 4, 2008
Adjunct thrombus aspiration reduces mortality in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction with high-risk angiographic characteristicsAamir Javaid, Nauman H Siddiqi, Daniel H Steinberg, et al.
JAMA Internal Medicine|October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service MedicareCunlin Wang, Robert Kane, Mark Levenson, et al.
Circulation|February 24, 2006
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stentsPramod K Kuchulakanti, William W Chu, Rebecca Torguson, et al.
Lancet (London, England)|November 14, 2018
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsPedro Cahn, Juan Sierra Madero, José Ramón Arribas, et al.
Transfusion|January 28, 2021
Medical chart validation of inpatient diagnosis codes for transfusion-related acute lung injury 2013-2015Candace C Fuller, Vinod E Nambudiri, Caren Spencer-Smith, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
The Lancet. Infectious Diseases|February 9, 2019
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trialMichael Aboud, Richard Kaplan, Johannes Lombaard, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 21, 2023
End Point Considerations for Clinical Trials in Enteric HyperoxaluriaCraig B Langman, Dean Assimos, Melanie Blank, et al.
Antimicrobial Agents and Chemotherapy|January 3, 2022
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the <i>In Vitro</i> Potency of Cabotegravir or RilpivirineJerry L Jeffrey, Marty St Clair, Ping Wang, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
The American Journal of Cardiology|February 2, 2008
Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary interventionProbal Roy, Ashesh N Buch, Aamir Javaid, et al.
The American Journal of Cardiology|March 4, 2008
Adjunct thrombus aspiration reduces mortality in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction with high-risk angiographic characteristicsAamir Javaid, Nauman H Siddiqi, Daniel H Steinberg, et al.
JAMA Internal Medicine|October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service MedicareCunlin Wang, Robert Kane, Mark Levenson, et al.
Circulation|February 24, 2006
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stentsPramod K Kuchulakanti, William W Chu, Rebecca Torguson, et al.
Lancet (London, England)|November 14, 2018
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsPedro Cahn, Juan Sierra Madero, José Ramón Arribas, et al.
Transfusion|January 28, 2021
Medical chart validation of inpatient diagnosis codes for transfusion-related acute lung injury 2013-2015Candace C Fuller, Vinod E Nambudiri, Caren Spencer-Smith, et al.
Pageof 13